Combining DK210 (CD20) With BiTE’s to Block Cytokine Release Syndrome
Time: 12:00 pm
day: Conference Day Two
Details:
- Combining anti-CD19 BiTE’s in vitro dramatically enhances T cell cytolysis of tumors when combined with as low as 0.1 ng/mL BiTE concentrations
- Blunting BiTE mediated cytokine release syndrome
- Enhancing tumor responses while suppressing CRS, suggesting DK210 (tumor target) may represent a potent combination partner with BiTE platforms
